2- (1,1- dicyanopropenyl- 2- )- 6- dimethylaminonaphthaleney

04/01/2014 - "Synthesis of superparamagnetic iron oxide nanoparticles coated with a DDNP-carboxyl derivative for in vitro magnetic resonance imaging of Alzheimer's disease."
11/01/2003 - "2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease."
01/01/2015 - "The detection of β-amyloid plaques in an Alzheimer's disease rat model with DDNP-SPIO."
04/01/2014 - "The DDNP-SPIONs were then further analyzed for their MRI relaxation properties using MR imaging and demonstrated high T2 relaxivity of 140.57s(-1)FemM(-1), and the vitro experiment that DDNP-SPIONs binding to β-Amyloid aggregates were then investigated by fluorophotometry, the results showed that the combination had induced the fluorescence enhancement of the DDNP-SPIONs and displayed tremendous promise for use as a contrast agent of Alzheimer's disease in MRI. "
04/01/2014 - "In this work, we synthetized an efficient contrast agent of Alzheimer's disease using 1,1-dicyano-2-[6-(dimethylamino)naphthalene-2-yl]propene (DDNP) carboxyl derivative to functionalize the surface of SPIONs. "

01/01/2020 - "This demonstrates that the information contained in the few features measured with dDNP NMR, is sufficient and robust for performing binary classification based on the metabolic activity of cultured prostate cancer cells."
01/01/2020 - "In this study, we used hyperpolarization in the form of dissolution Dynamic Nuclear Polarization (dDNP) NMR to measure signal enhanced isotope labelled metabolites reporting on pathway activity from four different prostate cancer cell lines. "
10/01/2020 - "Our results indicate that glucose and pyruvate metabolism in the prostate cancer cell models differs from that in other tumor models and that [18 F]FDG-PET can serve as a valuable complementary tool in dDNP studies of aggressive prostate cancer with [1-13 C]pyruvate."

08/16/2016 - "G-DDNPs are more potent than the corresponding free drugs and untargeted DDNP, showing that some synergistic and tumor-specific effects are achieved by this strategy. "
01/01/2021 - "Compared with the untreated group, tumors following BRAFi, aPDL1, and CSF1R-blocking antibody combination therapy did not show greater levels of TAM or DDNP (P = .82). "
01/01/2021 - "BRAFi and aPDL1 combination therapy resulted in higher tumor DDNP delivery by 39% ± 14 in pulmonary lesions (P = .004). "
05/05/2019 - "This indicated the likely utility of this approach in clinical dDNP of the human breast and may be useful as guidance for treatment response assessment in a large number of tumor types and therapies ex vivo."
10/01/2020 - "Our results indicate that glucose and pyruvate metabolism in the prostate cancer cell models differs from that in other tumor models and that [18 F]FDG-PET can serve as a valuable complementary tool in dDNP studies of aggressive prostate cancer with [1-13 C]pyruvate."

01/01/2015 - "The detection of β-amyloid plaques in an Alzheimer's disease rat model with DDNP-SPIO."
01/01/2015 - "To detect the β-amyloid plaques (Aβ) in a rat model of Alzheimer's disease (AD) using superparamagnetic iron oxide nanoparticles coated with 1,1-dicyano-2-[6-(dimethylamino)-naphthalene-2-yl] propene carboxyl derivative (DDNP-SPIO). "
01/01/2002 - "The authors used 2-(1-(6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl)ethylidene)malononitrile ([18F]FDDNP), a hydrophobic radiofluorinated derivative of 2-(1-[6-(dimethylamino)-2-naphthyl]ethylidene)malononitrile (DDNP), in conjunction with positron emission tomography to determine the localization and load of neurofibrillary tangles (NFTs) and beta-amyloid senile plaques (APs) in the brains of living Alzheimer disease (AD) patients. "

07/01/2011 - "Sixteen battle wounds were made by explosion of same type detonator (pattern number: 660929F48840-55, included DDNP 0.3 g, RDX 0.7 g) in hibateral skin of buttock of 8 pigs, which were divided into experimental group and control group (pair wounds of left and right). "